Serum apolipoprotein C-II is prognostic for survival after pancreatic resection for adenocarcinoma

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1883-1891

  Xue, A ^a   Chang, J W ^a   Chung, L ^b   Samra, J ^a   Hugh, T ^a   Gill, A ^b   Butturini, G ^c   Baxter, R C ^b   Smith, R C ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

apolipoproteins; biomarkers; pancreatic neoplasms; pancreaticoduodenectomy; prognosis; survival

Indexed keywords

APOLIPOPROTEIN C2; CA 19-9 ANTIGEN; SERUM AMYLOID A;

ADULT; AGED; AMINO ACID SEQUENCE; CANCER GROWTH; CANCER INVASION; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HAZARD ASSESSMENT; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PANCREAS RESECTION; PANCREATICODUODENECTOMY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; REVIEW; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN C-II; BLOTTING, WESTERN; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SERUM AMYLOID A PROTEIN; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84870047562     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.458     Document Type: Review

References (44)

1. Akizuki E, Kimura Y, Nobuoka T, Imamura M, Nishidate T, Mizuguchi T, Furuhata T, Hirata K (2008) Prospective nonrandomized comparison between pylorus-preserving and subtotal stomach-preserving pancreaticoduodenectomy from the perspectives of DGE occurrence and postoperative digestive functions. J Gastrointest Surg 12(7): 1185-1192
2. American joint Committee on cancer (2009) Cancer Staging Handbook. Springer: Chicago
3. Argiles JM, Busquets S, Toledo M, Lopez-Soriano FJ (2009) The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care 3(4): 263-268
4. Aslani A, Gill AJ, Roach PJ, Allen BJ, Smith RC (2010) Preoperative body composition is influenced by the stage of operable pancreatic adenocarcinoma but does not predict survival after Whipple's procedure. HPB (Oxford) 12(5): 325-333
5. Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP (2004) Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 11(7): 644-649
6. Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI (2010) Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte vs plateletlymphocyte ratio. Am J Surg 200(2): 197-203
7. Bunger S, Laubert T, Roblick UJ, Habermann JK (2011) Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview. J Cancer Res Clin Oncol 137(3): 375-389
8. Butturini G, Stocken DD, Wente MN, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Dervenis C, Bassi C, Buchler MW, Neoptolemos JP (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143(1): 75-83
9. Cao L, Wang L, Wang G, Liu D, Yu J, Que R, Xie D (2010) Evaluation of the effectiveness of a chemoprevention model of pancreatic adenocarcinoma using protein chip technology. Int J Oncol 37(6): 1515-1520
10. Castellanos EH, Cardin DB, Berlin JD (2011) Treatment of early-stage pancreatic cancer. Oncology (Williston Park) 25(2): 182-189
11. Chen J, Anderson M, Misek DE, Simeone DM, Lubman DM (2007) Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A 1162(2): 117-125
12. Chua W, Charles KA, Baracos VE, Clarke SJ (2011) Neutrophil/lymphocyte ratio predicts chemotherapy outcomes in patients with advanced colorectal cancer. Br J Cancer 104(8): 1288-1295
13. Distler M, Kersting S, Ruckert F, Dobrowolski F, Miehlke S, Grutzmann R, Saeger HD (2010) Palliative treatment of obstructive jaundice in patients with carcinoma of the pancreatic head or distal biliary tree. Endoscopic stent placement vs. hepaticojejunostomy. JOP 11(6): 568-574
14. Dogan UB, Gumurdulu Y, Golge N, Kara B (2011) Relationship of CA 19-9 with choledocholithiasis and cholangitis. Turk J Gastroenterol 22(2): 171-177
15. Felix K, Fakelman F, Hartmann D, Giese NA, Gaida MM, Schnolzer M, Flad T, Buchler MW, Werner J (2011) Identification of serum proteins involved in pancreatic cancer cachexia. Life Sci 88(5-6): 218-225
16. Firpo MA, Gay DZ, Granger SR, Scaife CL, DiSario JA, Boucher KM, Mulvihill SJ (2009) Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 33(4): 716-722
17. Giannopoulos G, Pavlakis K, Parasi A, Kavatzas N, Tiniakos D, Karakosta A, Tzanakis N, Peros G (2008) The expression of matrix metalloproteinases-2 and-9 and their tissue inhibitor 2 in pancreatic ductal and ampullary carcinoma and their relation to angiogenesis and clinicopathological parameters. Anticancer Res 28(3B): 1875-1881
18. Gill AJ, Johns AL, Eckstein R, Samra JS, Kaufman A, Chang DK, Merrett ND, Cosman PH, Smith RC, Biankin AV, Kench JG (2009) Synoptic reporting improves histopathological assessment of pancreatic resection specimens. Pathology 41(2): 161-167
19. Hallemeier CL, Botros M, Corsini MM, Haddock MG, Gunderson LL, Miller RC. (2011) Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy 8. Am J Clin Oncol 34(6): 567-572
20. Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, Kosuge T (2012) Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 19(2): 636-641
21. Jamieson NB, CR Carter, McKay CJ, Oien KA (2011) Tissue biomarkers for prognosis in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis. Clin Cancer Res 17(10): 3316-3331
22. Kardassis D, Roussou A, Papakosta P, Boulias K, Talianidis I, Zannis VI (2003) Synergism between nuclear receptors bound to specific hormone response elements of the hepatic control region-1 and the proximal apolipoprotein C-II promoter mediate apolipoprotein C-II gene regulation by bile acids and retinoids. Biochem J 372(Part 2): 291-304
23. Kim SY, Park SM, Lee ST (2006) Apolipoprotein C-II is a novel substrate for matrix metalloproteinases. Biochem Biophys Res Commun 339(1): 47-54
24. Kondo N, Murakami Y, Uemura K, Hayashidani Y, Sudo T, Hashimoto Y, Nakashima A, Sakabe R, Shigemoto N, Kato Y, Ohge H, Sueda T (2010) Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 17(9): 2321-2329
25. Manak E, Merkel S, Klein P, Papadopoulos T, Bautz WA, Baum U (2009) Resectability of pancreatic adenocarcinoma: assessment using multidetector-row computed tomography with multiplanar reformations. Abdom Imaging 34(1): 75-80
26. Manley PN, Ancsin JB, Kisilevsky R (2006) Rapid recycling of cholesterol: the joint biologic role of C-reactive protein and serum amyloid A. Med Hypotheses 66(4): 784-792
27. Mehta J, Prabhu R, Eshpuniyani P, Kantharia C, Supe A (2010) Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies. Trop Gastroenterol 31(3): 190-194
28. Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R (2012) CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol 33(3): 799-807
29. Pine JK, Fusai KG, Young R, Sharma D, Davidson BR, Menon KV, Rahman SH (2009) Serum C-reactive protein concentration and the prognosis of ductal adenocarcinoma of the head of pancreas. Eur J Surg Oncol 35(6): 605-610
30. Raynes JG, Cooper EH (1983) Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J Clin Pathol 36(7): 798-803
31. Samra JS, Gananadha S, Gill A, Smith RC, Hugh TJ (2006) Modified extended pancreatoduodenectomy: en bloc resection of the peripancreatic retroperitoneal tissue and the head of pancreas. ANZ J Surg 76(11): 1017-1020
32. Sato N, Fukushima N, Chang R, Matsubayashi H, Goggins M (2006) Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology 130(2): 548-565
33. Schnelldorfer T, Ware AL, Sarr MG, Smyrk TC, Zhang L, Qin R, Gullerud RE, Donohue JH, Nagorney DM, Farnell MB (2008) Long-term survival after pancreatoduodenectomy for pancreatic adenocarcinoma: is cure possible? Ann Surg 247(3): 456-462
34. Tang D, Zhang JQ, Wang DR (2011) Long term results of pancreatectomy with portal-superior mesenteric vein resection for pancreatic carcinoma: a systematic review. Hepatogastroenterology 58(106): 623-631
35. Tsavaris N, Kosmas C, Papadoniou N, Kopteridis P, Tsigritis K, Dokou A, Sarantonis J, Skopelitis H, Tzivras M, Gennatas K, Polyzos A, Papastratis G, Karatzas G, Papalambros A (2009) CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis. J Chemother 21(6): 673-680
36. Valkovskaya N, Kayed H, Felix K, Hartmann D, Giese NA, Osinsky SP, Friess H, Kleeff J (2007) ADAM8 expression is associated with increased invasiveness and reduced patient survival in pancreatic cancer. J Cell Mol Med 11(5): 1162-1174
37. van der Hilst JC (2011) Recent insights into the pathogenesis of type AA amyloidosis. Scientific World Journal 11: 641-650
38. Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, Orntoft TF (1999) Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 45(1): 54-61
39. Wagholikar GD, Sikora SS, Pandey R, Prasad KK, Kumar A, Saxena R, Kapoor VK (2003) Morphological changes in bile ducts following preoperative biliary stenting. Indian J Gastroenterol 22(5): 166-169
40. Wang F, Kumagai-Braesch M, Herrington MK, Larsson J, Permert J (2009) Increased lipid metabolism and cell turnover of MiaPaCa2 cells induced by high-fat diet in an orthotopic system. Metabolism 58(8): 1131-1136
41. Waraya M, Yamashita K, Katagiri H, Ishii K, Takahashi Y, Furuta K, Watanabe M (2009) Preoperative serum CA19-9 and dissected peripancreatic tissue margin as determiners of long-term survival in pancreatic cancer. Ann Surg Oncol 16(5): 1231-1240
42. Weinstein PS, Skinner M, Sipe JD, Lokich JJ, Zamcheck N, Cohen AS (1984) Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand J Immunol 19(3): 193-198
43. Xue A, Scarlett CJ, Chung L, Butturini G, Scarpa A, Gandy R, Wilson SR, Baxter RC, Smith RC (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br J Cancer 103(3): 391-400
44. Xue A, Xue M, Jackson C, Smith RC (2009) Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling. Int J Biochem Cell Biol 41(8-9): 1731-1738